These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34531667)

  • 1. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
    Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
    Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective.
    Paly VF; Li S; Khanduri P; Asfaw AA; Zou D; Hernandez L
    J Med Econ; 2024; 27(1):1076-1085. PubMed ID: 39102473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
    Nikolaou A; Ambavane A; Shah A; Ma W; Tosh J; Kapetanakis V; Willson J; Wang F; Hogea C; Gorsh B; Gutierrez B; Sapra S; Suvannasankha A; Samyshkin Y
    Expert Rev Hematol; 2021 Dec; 14(12):1137-1145. PubMed ID: 34465265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma.
    Bassali J; Gould IG; Kaye JA; Mladsi D; Mehta J
    Clinicoecon Outcomes Res; 2020; 12():317-325. PubMed ID: 32606848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
    Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
    J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
    Becnel MR; Lee HC
    Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
    Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
    Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
    Ghanem B; Shi L
    Clin Drug Investig; 2022 Dec; 42(12):1085-1092. PubMed ID: 36316586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 11. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 12. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
    Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
    Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos MV; Reddy N; Hakim S; LaMacchia J; Patel N; Williams D; Jewell RC; Zhou X; Gupta I; Opalinska J; Nooka AK
    Cancer; 2024 Aug; 130(15):2629-2641. PubMed ID: 38630908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.
    Abraham I; Calamia M; Alkhatib N; Pondel M; MacDonald K
    J Med Econ; 2024; 27(sup3):36-50. PubMed ID: 39359042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.
    Lubinga SJ; Walder L; Burton M; Shen Q
    J Med Econ; 2024; 27(1):1212-1221. PubMed ID: 39254489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
    Reece D; Diels J; Van Sanden S; Pei L; Ammann E; Heuck C; Kane C; Londhe A; Peterson S; Chari A
    Curr Med Res Opin; 2024 Oct; 40(10):1769-1783. PubMed ID: 39226081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory
    Pandya BJ; Yang H; Schmeichel C; Qi CZ; Shah MV
    J Med Econ; 2021; 24(1):19-28. PubMed ID: 33280474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma.
    Dolph M; Tremblay G; Leong H
    Clinicoecon Outcomes Res; 2021; 13():493-502. PubMed ID: 34140789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
    Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
    Front Oncol; 2021; 11():678634. PubMed ID: 34046363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
    Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
    J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.